pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 28·1 min read
save

Erasca appoints Charles Fuchs, former Tubulis CMO, as president of research and development

Aug 28, 2026·read at STAT ↗Neutral

STAT+ columnist Ed Silverman highlighted a recent personnel change in the pharmaceutical sector. The regular "comings and goings" feature tracks hires, promotions, and departures across the industry.

Erasca announced the hiring of Charles Fuchs to lead its research and development division as president. The move is part of the company's effort to strengthen its pipeline and scientific leadership.

Fuchs joins Erasca after serving as chief medical officer at Tubulis, bringing experience in drug development and clinical strategy to his new role.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
463 words · retrieved Aug 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECARISINGTEVA PHARMACEUTICAL INDUSTRIES LTD
topics
ApprovalGLP-1 receptorOncologyVaccine

related stories

  • Aug 31STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and moreSTAT
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Oct 1Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOFierce Biotech
  • Sep 29STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsSTAT
  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT